newsfilter
← Latest News
GlobeNewswire·

ChemoCentryx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

-- Total revenue of $32.2 million in 2021 with $2.3 million in Q4; TAVNEOS® (avacopan) US net product sales of approximately $1.0 million in Q4 2021 following US Food and Drug Administration (FDA) approval in ANCA-associated vasculitis -- -- TAVNEOS